Stock Analiz

Aytu Biopharma, Inc. AYTU

Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026

$1.78Market cap $19M
Open the interactive analysis →

Aytu Biopharma, Inc. (AYTU) is a healthcare company listed in the US with a market value of about $19M. In fiscal year 2026 it had revenue of $58M and net income of -$14M, a net margin of -24.8%.

Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is financial health (2/5); the weakest is future growth (0/5).

Key numbers: a price to free cash flow of 5.9, 5-year revenue growth of -3% a year, a 5-year average ROIC of -47%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 63% below the current price.

About Aytu Biopharma

Aytu Biopharma is listed in the US and classified in biotechnology: pharmaceutical preparations. Revenue went from $261782 in 2015 to $58M in 2026, growth of about 63.3% a year. It was profitable in 0 of the last 10 years in our data. Its share count rose by 269% over three years (dilution for shareholders).

Score: 0.8 / 5

Value1/5
Future growth0/5
Track record0/5
Financial health2/5
Shareholder returns1/5

Checks passed

  • P/FCF below 20
  • More cash than debt, or low debt to equity
  • Positive free cash flow
  • Stock-based pay below 5% of revenue

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving
  • 3-year free cash flow growth above 10% a year

Valuation

P/E (TTM)—
Forward P/E—
P/FCF5.9
P/S0.3
P/B0.5
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield16.8%
Shareholder yield0.0%
Intrinsic value vs. price−63%

Growth and quality

Revenue growth (1 yr)-13.3%
Revenue growth (5 yrs, per year)-2.6%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-39.6%
ROIC (5-yr avg.)-46.6%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 10 years

Fiscal year2026202520242023202220212020201920182017
Revenue$58M$66M$65M$107M$97M$66M$28M$7M$4M$3M
Net income-$14M-$14M-$16M-$17M-$109M-$58M-$14M-$27M-$10M-$23M
Free cash flow$3M-$2M-$2M—-$29M-$28M-$28M-$14M-$16M-$14M
EPS (diluted)$-1.16$-2.16$-2.86$-5.11$-74.01$-69.60$-60.20$-696.00$-3062.00$-9660.00
Net margin-24.8%-20.4%-24.3%-15.9%-112.5%-88.8%-49.3%-370.6%-278.4%-698.7%
ROIC-13.9%-18.8%-3.0%-30.3%-167.1%-29.4%-21.8%-187.8%-115.9%-397.5%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Is Aytu Biopharma stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 63% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Aytu Biopharma pay a dividend?

Not currently.

Is Aytu Biopharma a good stock to buy?

We do not give buy or sell advice. Aytu Biopharma scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.